|
KMID : 1001020130110010006
|
|
Journal of Urologic Oncology
2013 Volume.11 No. 1 p.6 ~ p.10
|
|
|
Risk Factors for Metastatic Castrate-Resistant Prostate Cancer
|
|
Kim Jae-Heon
Yang Won-Jae
|
|
|
Abstract
|
|
|
|
Prostate cancer remains the most common type of cancer in men and the development of castrate-resistant disease seems inevitable. Metastatic castrate-resistant prostate cancer(mCRPC) is known to have a poor prognosis although some new chemotherapy, immunotherapy, and target therapy showed improvement in overall survival, which together drive a new treatment strategy for better prognosis. For risk factors of mCRPC, it could be divided by the period of 2004, in which Docetaxel treatment was established as standard method for mCRPC. The aim of this study is to describe risk factors for the prognosis of mCRPC
|
|
|
KEYWORD
|
|
|
Castrate-resistant prostate cancer, Prognosis, Chemotherapy, Immunotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|